In summary, the Dutch study suggests proximal tumors likely have a lower absolute benefit in local control from the addition of selleck products radiation to surgery, while the MRC trial does not, despite showing that distal tumors are more likely to have positive CRM. Unfortunately, both trials include stage I to III disease, and neither trial addresses the

benefit of radiation based both on T stage and location. Specifically, the benefits of radiation in T3N0 proximal disease are of interest. Further study is needed Inhibitors,research,lifescience,medical to validate or refute the role of radiation in proximal T3N0 disease. Influence of nodal status As one would expect, the presence of malignant disease within regional lymph nodes increases the risk of local-regional recurrence.

Stocchi et al. retrospectively reviewed patients enrolled in 3 North Central Cancer Tumor Group (NCCTG) trials, and confirmed the prognostic value of nodal status on local-regional recurrence (24). Eligible patients Inhibitors,research,lifescience,medical had either T3-4 or N+ disease without distant metastases. Five-year local-regional failure rates for patients with T3 disease were 10%, 15%, and 32% for N0, N1, and N2, respectively. Gunderson et al. expanded the Stocchi analysis to include Inhibitors,research,lifescience,medical patients enrolled in NSABP R01 and R02 trials, for a total of 3791 evaluable patients (25). Again nodal involvement was predictive of local failure with recurrence rates of 9%, 11%, and 13% for N0, N1, and N2 disease, respectively Inhibitors,research,lifescience,medical (P=0.005). These authors evaluated outcomes with surgery alone, surgery plus chemotherapy, and surgery plus chemoradiation based on T stage and N stage (Table 3). Given the relatively low number of patients in certain subsets and given the retrospective nature of this study, the value of the addition of radiation to surgery and chemotherapy could Inhibitors,research,lifescience,medical not be answered. Nonetheless, the authors identified an intermediate risk group (T3N0, T1-2N1), a high intermediate risk group below (T1-2N2, T3N1,

T4N0), and a high risk group (T3-4N2, T4N1), and suggest that the intermediate risk group is the least likely to benefit from the addition of radiation therapy to chemotherapy. The studies included in this analysis were completed prior to the advent of TME and prior to the adoption of newer chemotherapies including oxaliplatin, and irinotecan. Furthermore, some utilized bolus rather than protracted venous 5FU, the latter of which has demonstrated superiority in a randomized trial (22). Therefore, the results of this study, while intriguing, are not directly applicable to the modern era. The use of TME and modern chemotherapy may further decrease the relative benefits of radiation, particularly in the intermediate risk group. Table 3 Gunderson et al.